---
category: trading
circular_id: f1c0e26ad603e230
date: '2025-12-30'
description: 'BSE revokes the suspension of trading in equity shares of Rekvina Laboratories
  Limited (Scrip Code: 526075), allowing normal trading to resume.'
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=59&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Revocation of trading suspension allows resumed trading activity for
  the company's equity shares, directly impacting shareholders and market participants.
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251230-9&attachedId=87682fdc-cc89-475e-a9de-1cb2933a1fdd
processing:
  attempts: 1
  content_hash: d73a0ffef8ac4a1f
  processed_at: '2025-12-30T18:58:25.472779'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-30T07:36:30+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=59&flag=0
severity: medium
source: bse
stocks:
- REKVINA
tags:
- trading
- suspension-revocation
- equity-shares
- pharmaceutical
- compliance
title: Revocation of Suspension in trading of equity shares of Rekvina Laboratories
  Ltd.
---

## Summary

BSE has revoked the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company is engaged in the pharmaceutical industry, providing quality medication at affordable prices. The company profile includes updated contact details, management information, and operational status.

## Key Points

- Trading suspension revoked for Rekvina Laboratories Limited equity shares
- Scrip Code: 526075
- ISIN: INE092O01028
- Company operates in pharmaceutical industry with focus on affordable medication
- Manufacturing facility located at GIDC Estate, Waghodia, Vadodara-391760
- Registered office at Sampatrao Colony, Alkapuri, Vadodara-390007
- Company is actively operational
- Group company: Radiant Parenterals Limited
- Listing fees paid to BSE

## Management Details

- Managing Director & Chairman: Amit Mukesh Shah (DIN: 01993211)
- Directors: Surbhit Mukesh Shah, Dhruvalkumar Patel, Chetanbhai Patel, Ilaben Pathak, Parteek Jain, Deepak Khandelwal
- Current Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for 2024-25 to 2028-29
- Previous Auditor: M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24)
- Auditor change was due to completion of statutory term

## Regulatory Changes

None specified. This circular represents a revocation of previous trading suspension rather than introduction of new regulatory requirements.

## Compliance Requirements

- Company has fulfilled listing compliance requirements
- Listing fees have been paid to BSE
- No actions taken against the company by other exchanges in the last five years
- No change in main line of business or company name in the last five years

## Important Dates

- Circular Date: December 30, 2025
- No specific effective dates mentioned for the revocation

## Impact Assessment

**Market Impact:** Medium - The revocation enables trading to resume, restoring liquidity for existing shareholders and allowing new market participants to trade the stock.

**Operational Impact:** Positive for the company as it can now access capital markets normally and shareholders can trade freely.

**Investor Impact:** Shareholders who were unable to exit positions during suspension can now trade their holdings. Potential investors can now participate in the stock.